Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood... (referred to in Novartis AG's current For...)

HOME >> BIOLOGY >> TECHNOLOGY

Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis

Date:11/6/2011

referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002

Post Your Comments:

(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...

(Date:5/23/2013)... , May 23, 2013 BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time. About BioScrip BioScrip, ...

(Date:5/23/2013)... 23, 2013 Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season. StemCyte, ... support awareness of umbilical cord blood banking and its ...

(Date:5/23/2013)... Calif. , May 23, 2013 Virobay, ... treatment for pain has reached an important milestone, as ... of VBY-036 - a selective cathepsin S inhibitor. ... is a double-blind, randomized, placebo-controlled study designed to evaluate ... of VBY-036 in healthy adults. "The initiation ...

Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2 Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3 Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4 Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5 StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2 StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3 Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2 Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3

[0] Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA [0] BioScrip To Present At Jefferies 2013 Global Healthcare Conference [0] StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 [0] Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain

... , , , BRISBANE, ... results from operations for the second quarter and six months ended June 30, ... of 2009 of $36.7 million, or $0.81 per share, compared with a net ... 2008. , , Dan Welch, Chairman, Chief Executive ...

... ... Improved Website. The New Site Provides Users With A Comprehensive Overview Of Pace Analytical ... Also Offers An Expanded Service Description For Each Of Its Three Major Business Divisions: ... ...

... , REDWOOD CITY, Calif., Aug. ... antibody therapeutics that target cancer stem cells, today announced the ... potent anti-cancer activity in colon and breast cancer models for ... of targeting cancer stem cells to treat solid tumors. ...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

(Date:5/22/2013)... physicists have developed a novel technique that can detect ... process that is one of the most important, though ... in a paper in Nature , post-doctoral researcher ... Melanie Schnell of the Center for Free-Electron Laser Science ... on finely-tuned microwave fields to identify molecular variants apart, ...

(Date:5/22/2013)... environmental and human health effects from disposal of ... led scientists to recommend stronger government policies to ... battery materials. That,s the conclusion of a new ... & Technology . , Oladele A. Ogunseitan and ... mainstays for powering everything from smart phones to ...

(Date:5/22/2013)... Early screening for prostate cancer could become as easy ... thanks to UC Irvine research published today in the ... After more than a decade of work, UC Irvine ... usable markers for prostate cancer in urine, meaning that ... accuracy and at dramatically lower cost. The same technology ...

Breaking Biology News(10 mins):Detecting mirror molecules 2 Detecting mirror molecules 3 UCI chemists devise inexpensive, accurate way to detect prostate cancer 2 UCI chemists devise inexpensive, accurate way to detect prostate cancer 3

[0] Detecting mirror molecules [0] More emphasis needed on recycling and reuse of Li-ion batteries [0] UCI chemists devise inexpensive, accurate way to detect prostate cancer

... Extremely premature infants who screen positive for autism spectrum disorder ... autism. Rather, they may fail screening tests due to an ... presented Sunday, May 1, at the Pediatric Academic Societies (PAS) ... 110 U.S. children has ASD, a group of complex developmental ...

... born to obese mothers are at risk for iron ... a study to be presented Saturday, April 30, at ... In nonpregnant adults, obesity-related inflammation hinders the transport ... iron deficiency anemia. When a woman is pregnant, iron ...

... applauds the US Court of Appeals for the District of ... against the use of public funds for embryonic stem cell ... cell research and the nation,s scientific community. Most importantly, ... suffering from incurable diseases," says Susan L. Solomon, CEO of ...

Cached Biology News:Screening very preterm infants for autism at 18 months often inaccurate 2

Screening very preterm infants for autism at 18 months often inaccurate Maternal obesity puts infants at risk Statement: The New York Stem Cell Foundation on lifting ban of federal funds for stem cell research

Request Info...

...

Guinea Pig Complement...

Collected from sexually mature mice....

Biology Products:

High-Binding EIA 96 Well Strip Plates from Cayman Chemical Rabbit Complement from Equitech-Bio Guinea Pig Complement from GeneTex Mouse Complement Lyophilized Powder from Equitech-Bio